Researchers with genetic Alzheimer’s disease predisposition interviewed on National Public Radio
Three researchers discussed strategies for maintaining cognitive function after discovering their own genetic profiles contained a predisposition for Alzheimer’s disease.
After undergoing genetic testing, the researchers found they possessed two copies of the APOE4 gene variant, a biomarker increasing their likelihood of later developing Alzheimer’s disease to 60%, according to a report from NPR. The genotype — known as APOE4-4 — is present in up to 3% of the U.S. population and can present with earlier onset of the disease.
One of the researchers joined an online community in which she learned how observing the Mediterranean diet, regular exercise, adequate nightly sleep and stress reduction could improve cognitive health. She later joined an ongoing study exploring the benefits of a four-month regimen of vigorous mental and physical activity as well as advocated for funding to support Alzheimer’s disease research and drug development.
The second researcher, a neuropsychologist, realized he had a genetic susceptibility to Alzheimer’s disease early in life after several of his family members developed the disease. Through clinical trials, the researcher uncovered two monoclonal antibodies that were effective in removing amyloid plaques from the brain. Although, the agents were found to cause brain swelling and bleeding among patients with the APOE4-4 profile, the researcher has begun experimental studies to determine whether a novel compound could prevent amyloid plaques from forming in the first place. Already, preliminary findings have indicated that the drug could preserve parts of the brain associated with memory but didn’t halt cognitive decline in those presenting with symptoms
The third researcher working in biotechnology joined advocacy groups after discovering her APOE4-4 status. She has since worked to educate the public on what it means to have a genetic predisposition for Alzheimer’s disease and met with the U.S. Food and Drug Administration to push for the development of more treatment options in this patient population and a streamlined regulatory path for drug approvals.
Read more: NPR
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.